Board of Directors
Damaris B. Skouras | Founder, Chairman, Chief Executive Officer
Ms. Skouras, a co-founder of Olatec, served as President until 2013 when she became Chairman and CEO. Ms. Skouras has over 20 years of experience in pharmaceutical drug development. Ms. Skouras began her career in finance in 1982 as a Vice President at Allen & Company Inc., where she was responsible for several biotech and technology start-up companies from early inception through exit. In 1985, she became Founder, Chairman and CEO of Global Reach Management Company, an international advisory firm that has provided investment banking services to Olatec. Ms. Skouras sits on several for-profit and not-for-profit Boards of Directors, including those in the field of life sciences. Ms. Skouras received a BA from Stanford University in 1978 and an MBA from Harvard University in 1982.
Robert B. Barrow | Chief Operating Officer, Director
Mr. Barrow joined Olatec in 2009, was appointed Chief Operating Officer in 2011 and was elected to the Board of Directors in 2013. Mr. Barrow attended The Wayne Calloway School of Business & Accountancy at Wake Forest University, where he graduated summa cum laude receiving a BS in Finance with Honors in 2009. Mr. Barrow has also earned his Certified Financial Analyst (CFA) designation. While at Wake Forest University, Mr. Barrow received several awards for both academic excellence and service to the community.
Valentín Campos, Sr. | Director
Mr. Campos has over 40 years of extensive experience in the healthcare industry. In 1991, Mr. Campos founded Centrum Promotora Internacional, S.A. de C.V. (“Centrum”), where he currently serves as CEO. Centrum is dedicated to the manufacturing, importation, distribution and marketing of products and services for health, particularly in the area of clinical diagnosis. Centrum has received the “Top Partners in Latin America” award by Siemens Healthcare Diagnostics. From 1971 to 1991, Mr. Campos worked in the public sector at the Instituto Mexicano del Seguro Social (“IMSS”), the Mexican social security agency, as well as a health supplier for the workers of México, which is one of the largest hospital conglomerates in the world. Mr. Campos started as head of the maintenance division for Equipment and Infrastructure and later became Vice President of the Administration responsible for supplying all the goods used for the daily operation of about 5,000 medical units in more than 300 hospitals, with responsibility over a $30 billion annual budget. IMSS consists of approximately 700 hospitals, providing insurance coverage currently to approximately 70 million people. Mr. Campos is also the President of Alsava Corporation (“Alsava"), which is his family office that was founded in 2014 to make private equity investments in early-stage companies with high upside potential. Alsava first invested in Olatec in 2015. Both Mr. Campos and Mr. Mauricio Pontones, Alsava’s CEO, are involved in Olatec at the Board level. Mr. Campos is a member of the Cámara Nacional de la Industria Farmacéutica (“CANIFARMA”), the syndicate group for the pharmaceutical industry in México, and has served as the President of the Committee for Diagnostics and Reagents. Mr. Campos has also performed charitable work for Hospital General de México, México’s biggest hospital, sponsoring community programs such as the Children’s Ludoteca and the John Langdon Down Foundation. Mr. Campos earned a B.S. in electrical and mechanical engineering at Universidad Nacional Autónoma de México in 1966.
John F. Otto, Jr. | Director
Mr. Otto is currently a Principal and Managing Partner of Waterfront Partners, LLC, a private investment company. Previously, Mr. Otto’s career spanned 35 years as an investment banker, most recently with Salomon, Smith Barney/Citigroup where he was responsible for their global telecommunications practice and a member of the Management Committee of the investment bank. He has held several board positions of both publicly traded companies and philanthropic institutions. Mr. Otto is an honors graduate of Boston College, where he received his BS degree. He earned an MBA from Columbia University.
Howard D. Palefsky | Director
Mr. Palefsky has extensive experience as an entrepreneur, CEO, Board Chair, Director and investor in the pharmaceutical, life sciences, medical device, healthcare and health and wellness industries. He is currently an independent investor and additionally serves as a director and advisor to numerous healthcare companies. Businesses in which Mr. Palefsky played a significant role have achieved in excess of $3 billion of value creation, more than 40 product launches, 20 company formations and numerous private financings, IPOs and M&A transactions. From 2002 to 2015, Mr. Palefsky was a Managing Director at Montreux Equity Partners and was a Venture Partner at Montreux from 1999 to 2002. From 1978 to 1997, he was the Chairman, President, Chief Executive Officer, and Director of Collagen Corporation, a pioneer in the aesthetic medicine field, where he also served as an advisor from 1997 to 1999. At Collagen, Mr. Palefsky was brought in as CEO when the company was a pre-revenue start-up. He led Collagen through numerous financings (including its Initial Public Offering), product approvals and worldwide launches, and ultimately to profitability. Earlier, Mr. Palefsky was Vice President of Marketing at the ALZA Pharmaceuticals division of ALZA Corp. (which was later acquired by Johnson & Johnson) from 1973 to 1978 and a Marketing Manager at American Home Products (renamed to Wyeth, and subsequently acquired by Pfizer) from 1971 to 1973. Mr. Palefsky served as an officer in the United States Public Health Service from 1967 to 1969. He currently serves as a Board Member and Treasurer of the 21st Century Foundation of the City College of New York, and a Board Member of the Atlanta Symphony Orchestra and the Atlanta History Center. Mr. Palefsky earned a B.S. in Mathematics from City College of the City University of New York in 1967 and an MBA from Stanford University Graduate School of Business in 1971.
Lucio C. Rovati, MD | Director
In September 2015, Lucio C. Rovati, MD, joined Olatec’s Scientific Advisory Board. For Olatec, Dr. Rovati brings extensive experience in drug development and clinical programs, particularly in osteoarthritis. Dr. Rovati is CEO and CSO of Rottapharm Biotech S.r.l., the R&D spin-off of the former Rottapharm pharmaceutical company. Rottapharm Biotech is a company of biotechnologies committed to the discovery, research and development of new innovative therapeutic drugs, both chemical and biological in nature. Dr. Rovati is responsible for all scientific and R&D activities of the company, with direct reporting from all operative functions, including: medicinal chemistry, antibody discovery & protein engineering, pharmacology and toxicology, translational sciences and pharmacokinetics, pharmaceutical technology, biostatistics, clinical research, regulatory and quality, business development, scientific liaison and drug safety. Dr. Rovati has held numerous academic positions, the most recent of which was his appointment as Visiting Professor of Clinical Pharmacology at the University of Milano Bicocca School of Medicine in 2003. Dr. Rovati is a member of the American College of Rheumatology in addition to several other important scientific societies. He has authored or co-authored over 175 full papers published in peer reviewed international scientific journals and 15 book chapters. Related scientific activity includes authorship of over 400 abstracts and selected/invited presentations in international congresses. Dr. Rovati holds a degree in Medicine and Surgery from the University of Milano, with specialization in Clinical Pharmacology.
George A. Skouras | Director
Mr. Skouras is an international banker, corporate restructuring advisor, investor, and fundraiser over a 30-year career culminating with his formation of Cue Capital LP in 2003. Cue specializes in capital raising efforts for private equity managers and companies and in particular venture backed companies and venture groups. In this capacity, Cue has raised over $1.1 billion through Cue’s direct institutional sales efforts, more than half for life science and healthcare groups. Prior to forming Cue, Mr. Skouras was Managing Director and Board Member of Austrian based Creditanstalt BankVerein’s investment bank in New York and Russia. At Creditanstalt, his responsibilities included capital raising and asset management for companies and investment funds investing in Russia, Central and Eastern Europe. Mr. Skouras began his career at Citibank in 1978, working primarily in the Bank’s loan workout group restructuring distressed companies. Mr. Skouras also started one of the first distressed credit funds in 1987, Citicorp Turnaround Investments. In 1991, he was named Managing Director of Citicorp International Equity Investments investing in companies for Citicorp in emerging markets through privatizations. In 1992, he became the first Citibank country head for the Russian Federation. Mr. Skouras graduated with a BA in Russian and Economics in 1976 from Tufts University and studied for a Master’s Degree at the Paul Nitze School of Advanced International Studies at Johns Hopkins University (SAIS), where he was awarded the merit of Honors and Distinction in 1978.
Spyros S. Skouras, Jr. | Director
Mr. Skouras is currently a Principal and Managing Director of S Three Capital, LLC, a private investment company he founded which focuses on shipping and offshore industry investments. Previously, Mr. Skouras was a Senior Vice President of a Managing Partner for a series of private investment partnerships. He was also Vice President, Chief Operating Officer and a member of the Board of Directors of Prudential Grace Lines an international shipping company. Mr. Skouras has held several board positions of both publicly traded and private companies. Mr. Skouras graduated from Tufts University, where he received his BA degree in 1976, and he earned an MBA from Harvard University in 1980.
General Peter M. Dawkins, PhD, USA (Ret.) | Director Emeritus
Brigadier General Peter M. Dawkins, U.S. Army (Retired), has 30 years of business and financial expertise having served, from 1996 to 2007, as a Vice Chairman at Citigroup and its predecessor organizations, Travelers Group and Primerica Corporation. He is currently serving as Senior Advisor to a Manhattan-based, non-bank liquidity providing firm: Virtu Financial. In 1983, Gen. Dawkins began his career in the private sector as a Partner at Lehman Brothers, where he headed the Public Finance Banking business. Later he ran the U.S. Consulting practice at Bain & Company and, from 1991 to 1995, was Chairman and CEO of Primerica Financial Services. Gen. Dawkins served as a Director of Iridium Communications Inc. from November 2009 to December 2015. He is also a member of the Advisory Boards of Wilmington Trust FSB and Manchester Capital Management. During his military career, he was Military Assistant to the Deputy Secretary of Defense and was selected as a White House Fellow. Gen. Dawkins commanded a company in the 82nd Airborne Division, led a battalion in Korea and commanded a brigade of the 101st Airborne Division. He is a decorated combat leader and was promoted to Brigadier General in 1981. In 1972, he received the Gold Medal Award from the National Institute of Social Sciences. In 1976, Time Magazine identified him as one of the “Top 50 Leaders in the United States.” In 2006, he received the Horatio Alger Award. Gen. Dawkins was the Republican candidate for the United States Senate for the state of New Jersey in 1988, and is the 1958 winner of college football’s Heisman Trophy. He remains active in a variety of national, community and philanthropic roles. Gen. Dawkins’ listing of Board service includes the Intrepid Museum, the Wharton Business School’s Center for Leadership and Change Management, the Secretary of Defense Policy Board, and the Boards of Trustees of the United States Military Academy, Hampden-Sydney College, Emory University Business School and the Johns Hopkins School of Public Health. He is a 1959 graduate of West Point. Gen. Dawkins was selected as a Rhodes Scholar and holds a BA and MA from Oxford University. He also received an MPA and PhD from the Woodrow Wilson School at Princeton University.
Damaris D. W. Ford | Director Emeritus
Ms. Ford is the Founder of Landmark Vineyards, Proprietor of Wilomar Corporation and past part owner of Valuation Research in Milwaukee, WI. In addition to her many business ventures, Ms. Ford helped form the Flying Doctors of Africa; has served on the boards of the Freedom Institute; I.O.C. (an International Order of Characters, a flying club made up mostly of famous WWII aces); New York’s Lenox Hill Hospital; Sun Valley Center for the Arts and Humanities; Conservation International; the American Federation of Arts; Jupiter Island Club; and the Stamford Hospital Foundation where she is also a permanent member of their Emeritus Council. She has been involved in fundraising for many local and national charities.
John A. Georges | Director Emeritus
Mr. Georges is an Operating Partner in the Chemicals and Process Industries vertical for One Rock Capital Partners, LLC. Mr. Georges is currently the Chairman of One Rock’s portfolio companies Summit Research Labs and Compass Chemical. Mr. Georges served as a Ripplewood Industrial Partner from 1999 to 2009. Mr. Georges served as Chairman of Supresta LLC and Kraton Polymers LLC during Ripplewood’s ownership of those companies. Formerly, Mr. Georges was Chairman of the Board and Chief Executive Officer of International Paper from 1984 until his retirement in 1996. He served as President and Chief Operating Officer of International Paper from 1981 to 1984. Mr. Georges started his career with DuPont, where he spent 28 years in various positions, including General Manager of Textile Fibers and Chief Environmental Officer. Mr. Georges has been a member of several non-corporate organizations such as The Business Council; The Trilateral Commission; The Public Policy Institute of the Business Council of New York State (Trustee); The University of Illinois Foundation (current Board member; President from 1995 to 1997); and Chairman of the Executive Council of the Harvard University Center for Risk Analysis. He has also served as a Director of Warner-Lambert Company, Ryder System Inc., and AK Steel Holding Corporation. Mr. Georges was formerly a Director of the New York Stock Exchange (1987-1993), a Director of the Federal Reserve Bank of New York (1986-1992); and Member of the Policy and Planning Committee of the Business Roundtable (1987-1996). Mr. Georges earned a B.S. in chemical engineering from the University of Illinois and an MBA from Drexel University. In 2015, he was inducted to the Engineering Hall of Fame at the University of Illinois.
Donald M. Kendall | Director Emeritus
Mr. Kendall is the co-founder of PepsiCo and was its Chief Executive Officer for 21 years before his retirement in May 1986. Mr. Kendall also served as Chairman of the Executive Committee of PepsiCo’s Board of Directors from 1986 until 1991. A native of Sequim, Washington, Mr. Kendall attended Western Kentucky State College. He is the recipient of an Honorary Doctorate of Law Degree from Stetson University, an Honorary Doctorate of Law Degree from Babson College and a Doctor of Law from Gonzaga University. Mr. Kendall also received Doctor of Humane Letters degrees from Mercy College, Manhattanville College, the State University of New York (SUNY) Purchase and Long Island University.
J. Richard Steadman, MD | Director Emeritus
Olatec’s co-founder, J. Richard Steadman, MD, is a world-renowned KOL in the fields of Orthopaedics and Sports Medicine. Dr. Steadman is the Founder of the internationally known Steadman Clinic in Colorado. He has over 40 years of experience in the field of orthopaedics and is recognized worldwide for his innovative surgical procedures developed over time and employed today by orthopaedic surgeons practicing throughout the world. The Steadman Philippon Research Institute (SPRI) has one of the largest patient databases in existence, and its research supports the evidence-based practice of Orthopaedics at the Steadman Clinic. Dr. Steadman and the Institute have published over 70 research articles and have presented over 150 research papers at national and international conferences. In 2015, Dr. Steadman was inducted into the American Orthopaedic Society for Sports Medicine’s (AOSSM) Hall of Fame, honoring individuals in the sports medicine community who have contributed immensely and set themselves apart from others in the field. Dr. Steadman has also received a number of some of the most prestigious international medical awards and honors, including: the American Orthopedic Society for Sports Medicine, the Cabaud Award, the International Knee Society Albert Trillat Award, the Gots-Beiersdorf Research Award of Germany and the American Orthopaedic Society for Sports Medicine 2005 Award, among others. Following his internship at Charity Hospital in New Orleans, Dr. Steadman and his family spent two years in Germany, where he served as the Commander of an Armored Medical Company in the U.S. Army. He returned to Charity Hospital for his orthopaedics residency, which he completed in 1970. Dr. Steadman graduated from Texas A&M University in 1959 and then the Medical School at the University of Texas, Southwestern Medical School in 1963.
Spyros S. Skouras, Sr. | 2003-2013: Founder, CEO and Chairman of the Board